Advances in the effectiveness and safety of azvudine treatment: a comprehensive review DOI Creative Commons

Jiayi Li,

Bo Zhu, Jian Lü

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Апрель 25, 2025

The global impact of COVID-19 has highlighted the urgent need for effective therapeutic interventions against SARS-CoV-2. Azvudine, a dual-target nucleoside drug initially developed human immunodeficiency virus (HIV), gained attention its potential in treating COVID-19. On 25 July 2022, Azvudine received conditional approval from National Medical Products Administration (NMPA) China, making it first oral SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor treatment. This review explores pharmacological activity, antiviral mechanisms, and clinical effectiveness azvudine context Clinical trials have demonstrated ability to reduce viral load, shorten time nucleic acid negativity, improve outcomes patients. Additionally, shown excellent pharmacokinetic properties favorable safety profile with mild side effects. also addresses importance interactions considerations, particularly high-risk populations. Research should focus on optimizing second-generation inhibitors enhanced variants, improving bioavailability, minimizing adverse effects, ensuring more robust treatment options

Язык: Английский

Evaluation of the efficacy and mechanisms of azvudine in elderly patients with malignant tumors complicated by COVID-19 DOI Creative Commons
Ranran Sun, Yihang Song, Yiran Li

и другие.

Acta Pharmaceutica Sinica B, Год журнала: 2025, Номер 15(3), С. 1712 - 1714

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Advances in the effectiveness and safety of azvudine treatment: a comprehensive review DOI Creative Commons

Jiayi Li,

Bo Zhu, Jian Lü

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Апрель 25, 2025

The global impact of COVID-19 has highlighted the urgent need for effective therapeutic interventions against SARS-CoV-2. Azvudine, a dual-target nucleoside drug initially developed human immunodeficiency virus (HIV), gained attention its potential in treating COVID-19. On 25 July 2022, Azvudine received conditional approval from National Medical Products Administration (NMPA) China, making it first oral SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor treatment. This review explores pharmacological activity, antiviral mechanisms, and clinical effectiveness azvudine context Clinical trials have demonstrated ability to reduce viral load, shorten time nucleic acid negativity, improve outcomes patients. Additionally, shown excellent pharmacokinetic properties favorable safety profile with mild side effects. also addresses importance interactions considerations, particularly high-risk populations. Research should focus on optimizing second-generation inhibitors enhanced variants, improving bioavailability, minimizing adverse effects, ensuring more robust treatment options

Язык: Английский

Процитировано

0